Related Experiment Video
Updated: Aug 1, 2025

LED-Based In Vitro Screening for Assessing Photoactivable Molecules in Bacterial Photodynamic Inactivation
Published on: January 24, 2025
JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum
Luiz G M Castro1,2,3
1Oncoderma, São Paulo, Brazil.
Background:
Pyoderma gangrenosum currently lacks standardized therapy. New safer and more efficacious therapies are welcome.
Aims:
To present two new PG cases treated with JAK inhibitors, adding to the small existing experience METHODS & METHODS: Two case reports of PG patients successfully treated with tofacitinib and baricitinib.
Results:
Both patients were cured and presented no relapse. Patient # 1 used baricitinib 2 mg bid for 39 days while patient # 2 was treated with tofacitinib 5 mg bid for 120 days. No adverse reactions were seen.
Discussion:
The increasing usage of JAKi to treat inflammatory diseases had a positive reflex on PG therapy. Fifteen PG cases treated with these drugs had been found in literature and the two new cases here described add to the limited existing experience.
Conclusion:
This is a novel use of tofacitinib and baricitinib beyond the approved indications. JAKi are a welcome addition to our options to manage patients with PG.
More Related Videos
Related Concept Videos
Acute Pyelonephritis I: Introduction
Acute Pyelonephritis II: Diagnostic Studies and Management
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

